8-K filed Jun 29, 2026 at 06:30 ET
Theravance Biopharma (TBPH) entered into a definitive merger agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash plus one contingent value right (CVR) per share. The CVR entitles holders to 80% of net proceeds from any future monetization of ampreloxetine over ten years, plus a potential $50M milestone payment and 10% royalties on net sales. The all-cash deal values TBPH at approximately $929M equity value and is expected to close in H2 2026, subject to shareholder and regulatory approvals. The filing also includes employee communications (Item 7.01) and a press release (Item 8.01).